These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20440227)

  • 1. Clopidogrel pathway.
    Sangkuhl K; Klein TE; Altman RB
    Pharmacogenet Genomics; 2010 Jul; 20(7):463-5. PubMed ID: 20440227
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet aggregation pathway.
    Sangkuhl K; Shuldiner AR; Klein TE; Altman RB
    Pharmacogenet Genomics; 2011 Aug; 21(8):516-21. PubMed ID: 20938371
    [No Abstract]   [Full Text] [Related]  

  • 3. In brief: poor metabolizers of clopidogrel (plavix).
    Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
    [No Abstract]   [Full Text] [Related]  

  • 4. Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.
    Zhang H; Ragueneau-Majlessi I; Levy RH
    Drug Metab Lett; 2009 Dec; 3(4):287-9. PubMed ID: 19995331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV
    Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel in acute coronary syndrome: to genotype or not?
    Storey RF
    Lancet; 2009 Jan; 373(9660):276-8. PubMed ID: 19108882
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenomics and clopidogrel: irrational exuberance?
    Nissen SE
    JAMA; 2011 Dec; 306(24):2727-8. PubMed ID: 22203545
    [No Abstract]   [Full Text] [Related]  

  • 9. CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.
    Aleil B; Léon C; Cazenave JP; Gachet C
    J Thromb Haemost; 2009 Oct; 7(10):1747-9. PubMed ID: 19624462
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.
    Hulot JS; Wuerzner G; Bachelot-Loza C; Azizi M; Blanchard A; Peyrard S; Funck-Brentano C; Gaussem P
    J Thromb Haemost; 2010 Mar; 8(3):610-3. PubMed ID: 20040040
    [No Abstract]   [Full Text] [Related]  

  • 11. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.
    Umemura K; Furuta T; Kondo K
    J Thromb Haemost; 2008 Aug; 6(8):1439-41. PubMed ID: 18532997
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
    Perry E
    Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical significance of interactions between clopidogrel and proton pump inhibitors].
    Kubica A; Koziński M; Grześk G; Goch A
    Kardiol Pol; 2011; 69(6):610-6. PubMed ID: 21678305
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
    Beitelshees AL; Horenstein RB; Vesely MR; Mehra MR; Shuldiner AR
    Clin Pharmacol Ther; 2011 Mar; 89(3):455-9. PubMed ID: 21270785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.
    Fontana P; Hulot JS; De Moerloose P; Gaussem P
    J Thromb Haemost; 2007 Oct; 5(10):2153-5. PubMed ID: 17697139
    [No Abstract]   [Full Text] [Related]  

  • 17. Duration of clopidogrel therapy with drug-eluting stents.
    Rennings AJ; Schouwenberg BJ; van Onzenoort HA
    N Engl J Med; 2010 Jul; 363(5):489; author reply 490. PubMed ID: 20830829
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Ramaraj R
    Lancet; 2009 Apr; 373(9670):1172; author reply 1172-3. PubMed ID: 19345827
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clopidogrel and proton pump inhibitors: insufficient evidence of interaction].
    Hunfeld NG; Valkhoff VE; Touw DJ; Sturkenboom MC; Kuipers EJ
    Ned Tijdschr Geneeskd; 2011; 155(28):A2404. PubMed ID: 21771376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.